Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study
Abstract
Objectives To asses risk factors for a first thrombotic event in antiphospholipid antibody (aPL) positive carriers and evaluate the efficacy of prophylactic treatments. Methods Recruitment criteria were age 18-65 years, no history of thrombosis, positivity for lupus anticoagulant and/or IgG/IgM anticardiolipin antibody (aCL) on > or =2 occasions at least 6 weeks apart. Demographic, laboratory and clinical parameters were collected at enrolment and at the time of the thrombotic event. Results 370 patients/subjects (mean (SD) age 34 (9.9) years) were analysed retrospectively for a mean (SD) follow-up of 59.3 (45.5) months. Thirty patients (8.1%) developed a first thrombotic event during follow-up. Hypertension and medium/high levels of IgG aCL were identified by multivariate logistic regression analysis as independent risk factors for thrombosis. Thromboprophylaxis during high-risk and long-term periods was significantly protective. Conclusions Hypertension or medium/high titres of IgG aCL are risk factors for a first thrombotic event in asymptomatic aPL carriers and primary prophylaxis is protective.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pregnancy is not associated with thrombosis in antiphospholipid antibody carriers in this study.
“In agreement with previously reported findings, 1,15 pregnancy was not associated with thrombosis in our patients.”
From Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. (2011) · cites this paper as [15]
The number of thrombotic events in this study was similar to that reported in other studies and in the authors' own retrospective study.
“Finally, the number of thrombotic events was rather low (incidence rate 1.86% per 100 patients per year) and similar to that reported in other studies [1][2][3]7,8,13,16 and by our own retrospective study.15”
From Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. (2011) · cites this paper as [15]
In the authors' previous retrospective study, long-term thromboprophylaxis management and management during high-risk periods were independent protective factors against thrombosis only when considered together, but when analysed separately, none was protective.
“Long-term thromboprophylaxis management and management during high-risk periods were, moreover, found to be independent protective factors against thrombosis only when considered together but, when analysed separately, none was protective against thrombosis.”
From Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. (2011) · cites this paper as [15]
In the authors' previous retrospective study, hypertension and medium/high titres of IgG anticardiolipin antibodies are independent predictors of thrombosis.
“Our results showed that hypertension and medium/high titres of IgG anticardiolipin antibodies (aCL) are independent predictors of thrombosis.”
From Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. (2011) · cites this paper as [15]
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203 · see citing works
Self-citationAnticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis
Ginsburg, K. S., Liang, M. H., Newcomer, L., Goldhaber, S. Z., Schur, P. H., Hennekens, C. H., & Stampfer, M. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-997 · Cited by 526 · see citing works
Erkan, D., Harrison, M. J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., Unalp‐Arida, A., Vilela, V., Yazici, Y., & Lockshin, M. D. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22663 · Cited by 401 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Ruiz-Irastorza, G., Cuadrado, M., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V, et al. (2011) · Lupus · doi:10.1177/0961203310395803 · Cited by 506 · see citing works
GAPSS: the Global Anti-Phospholipid Syndrome Score
Sciascia, S., Sanna, G., Murru, V., Roccatello, D., Khamashta, M. A., & Bertolaccini, M. L. (2013) · Rheumatology · doi:10.1093/rheumatology/kes388 · Cited by 318 · see citing works
Arnaud, L., Mathian, A., Ruffatti, A., Erkan, D., Tektonidou, M., Cervera, R., Forastiero, R., Pengo, V., Lambert, M., Martinez-Zamora, M. A., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.10.014 · Cited by 215 · see citing works
Self-citationRuffatti, A., Del Ross, T., Ciprian, M., Bertero, M. T., Salvatore, S., Scarpato, S., Montecucco, C., Rossi, S., Caramaschi, P., Biasi, D., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.142042 · Cited by 184 · see citing works
Self-citationYelnik, C. M., Urbanski, G., Drumez, E., Sobanski, V, Maillard, H., Lanteri, A., Morell-Dubois, S., Caron, C., Dubucquoi, S., Launay, D., et al. (2017) · Lupus · doi:10.1177/0961203316657433 · Cited by 73 · see citing works
Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?
Barbhaiya, M., & Erkan, D. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-010-0149-3 · Cited by 69 · see citing works
Erkan, D., Unlu, O., Sciascia, S., Belmont, H. M., Branch, D. W., Cuadrado, M. J., Gonzalez, E., Knight, J. S., Uthman, I., Willis, R., et al. (2018) · Lupus · doi:10.1177/0961203317724219 · Cited by 67 · see citing works
- Authors
- Ruffatti, A., Ross, T. D., Ciprian, M., Nuzzo, M., Rampudda, M., Bertero, M. T., Bergia, R., Caramaschi, P., Biasi, D., Capsoni, F., Montaguti, L., Ruffini, R., Brucato, A., Picillo, U., Fanelli, V, Riccieri, V, Piccoli, A., Valesini, G., Doria, A., Meroni, P. L., & Tincani, A.
- Affiliations
- University of Padua (IT)
- University of Brescia (IT)
- A. O. Ordine Mauriziano di Torino (IT)
- University of Verona (IT)
- University of Milan (IT)
- Ospedale “M. Bufalini” di Cesena (IT)
- University of Naples Federico II (IT)
- Sapienza University of Rome (IT)
- Corresponding author
- Ruffatti, A
- ORCID
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2009-03
- Volume
- 68
- Issue
- 3
- Pages
- 397-399
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2122755842
- Cited by
- 106
- References
- 3
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 5 · 2019: 7 · 2018: 5 · 2017: 5 · 2016: 9 · 2015: 7 · 2014: 7 · 2013: 15 · 2012: 10
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of the Rheumatic Diseases (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vasculitis and related conditions
- Keywords
- antiphospholipid antibodies, thrombosis risk factors, lupus anticoagulant, anticardiolipin antibodies, IgG anticardiolipin antibodies, hypertension, thromboprophylaxis
- MeSH terms
- Adolescent, Adult, Aged, Epidemiologic Methods, Female, Heterozygote, Humans, Hypertension, Immunoglobulin G, Male, Middle Aged, Thrombosis, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Antibodies, Anticardiolipin, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
